Pfizer (PFE) Non-Current Deferred Tax Liability (2016 - 2025)
Historic Non-Current Deferred Tax Liability for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $2.5 billion.
- Pfizer's Non-Current Deferred Tax Liability rose 1431.88% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 1431.88%. This contributed to the annual value of $2.1 billion for FY2024, which is 8687.86% down from last year.
- Per Pfizer's latest filing, its Non-Current Deferred Tax Liability stood at $2.5 billion for Q3 2025, which was up 1431.88% from $2.5 billion recorded in Q2 2025.
- In the past 5 years, Pfizer's Non-Current Deferred Tax Liability ranged from a high of $16.2 billion in Q4 2023 and a low of $328.0 million during Q4 2021
- In the last 5 years, Pfizer's Non-Current Deferred Tax Liability had a median value of $2.2 billion in 2024 and averaged $3.3 billion.
- Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first tumbled by 9277.85% in 2021, then soared by 14253.49% in 2025.
- Over the past 5 years, Pfizer's Non-Current Deferred Tax Liability (Quarter) stood at $7.7 billion in 2021, then grew by 23.4% to $9.5 billion in 2022, then skyrocketed by 69.89% to $16.2 billion in 2023, then crashed by 86.88% to $2.1 billion in 2024, then rose by 16.26% to $2.5 billion in 2025.
- Its Non-Current Deferred Tax Liability was $2.5 billion in Q3 2025, compared to $2.5 billion in Q2 2025 and $2.3 billion in Q1 2025.